Dr. Johnson on the Need for Novel Biomarkers in Melanoma

Source: OncLive, September 2020

Douglas B. Johnson, MD, MSCI, assistant professor of medicine, Vanderbilt University Medical Center, clinical director, Melanoma Research Program, Vanderbilt-Ingram Cancer Center, discusses the need to identify novel biomarkers in melanoma.

Although biomarkers such as BRAF mutations and PD-1/PD-L1 have assisted in treatment selection in the melanoma space, identifying additional biomarkers has been challenging, says Johnson.

In particular, it has been difficult to develop a biomarker that can inform when to use anti-PD-1 monotherapy, combination therapy, BRAF/MEK inhibition, or next-generation therapies such as intratumoral injections or tumor-infiltrating lymphocyte therapy.

READ THE ORIGINAL FULL ARTICLE